Business
BELLUS HEALTH ANNOUNCES PHASE I RESULTS OF PRODRUG NRM8499 INTENDED FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Jan. 31, 2011 (Canada NewsWire Group) -- Prodrug demonstrates improved gastrointestinal tol...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n Jan. 31, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nProdrug demonstrates improved gastrointestinal tolerability and\n pharmacokinetic profile over tramiprosate \n\n\nLAVAL, QUEBEC, Jan. 31 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or\n the "Company") announced today the results of the phase I clinical\n study for NRM8499, a prodrug of tramiprosate, intended for the\n treatment of Alzheimer's disease (the "Phase I Study"). The Phase I\n Study investigated the safety, tolerability and pharmacokinetic profile\n of NRM8499 as compared to tramiprosate in a group of 67 young and\n elderly healthy subjects. Results of the Phase I Study indicated that\n NRM8499 was safe and well tolerated at the intended therapeutic dose.\n Moreover, the gastrointestinal tolerability and pharmacokinetic profile\n of tramiprosate, with regards to the inter-individual variability in\n drug systemic exposure, were meaningfully improved with NRM8499 when\n compared to the administration of an equivalent dose of tramiprosate.\n\n\n"We are pleased with the results of the NRM8499 phase I clinical study,"\n said Roberto Bellini, President and Chief Executive Officer of BELLUS\n Health. "The results show a solid potential for pursuing NRM8499 for\n the treatment of Alzheimer's disease."\n\n\nAbout the Phase I Study \n\n\nThis randomized, double-blind, placebo-controlled Phase I Study was\n divided into three parts:\n\n\n\nPart o...